Related Experiment Video
Updated: Apr 8, 2026
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy
Hamidreza Montazeri Aliabadi1,2, Parvin Mahdipoor3, Cezary Kucharsky3
1School of Pharmacy, Chapman University, #211, 9401 Jeronimo Road, Irvine, California, 92618, USA. montazer@chapman.edu.
Purpose:
An alternative cancer therapy based on RNA interference (RNAi) has shown considerable promise but the possibility of resistance development is not known. This study explored the possibility of therapeutic resistance against siRNA nanoparticles in human cancer cells.
Methods:
Two approaches to siRNA treatment were undertaken using lipid-modified polyethylenimines, a single high concentration (shock) and repeated increasing concentrations (gradual). The targets were Mcl-1, RPS6KA5 and KSP in MDA-MB-435 cells.
Results:
There was no evidence of resistance development in shock-treated cells, while the decrease in mRNA levels of targeted proteins was not as robust in naïve cells in gradual treatment. However, silencing efficiency was restored after a 7-day recovery period when expression of suppressed proteins returned to normal levels. Cellular uptake of siRNA was not affected by pre-treatments. Other mediators involved in cell survival and proliferation were altered in siRNA-treated cells, but only JUN silencing led to a heightened loss of viability. In vivo experiments demonstrated similar silencing efficiency at mRNA level after repeat doses.
Conclusions:
Human cancer cells responded to repeat siRNA nanoparticles in a similar fashion after a temporary initial alteration and little, if any, resistance was evident against repeated siRNA treatments.
Insights
This study investigated therapeutic resistance to small interfering RNA (siRNA) nanoparticles in cancer. Researchers found little evidence of resistance developing, even with repeated treatments, suggesting siRNA nanoparticle therapy is a promising cancer treatment option.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- RNA interference (RNAi) offers a promising alternative cancer therapy.
- The potential for therapeutic resistance to RNAi treatments is largely unknown.
- Investigating resistance mechanisms is crucial for advancing siRNA nanoparticle therapies.
Purpose of the Study:
- To explore the development of therapeutic resistance to small interfering RNA (siRNA) nanoparticles in human cancer cells.
- To compare resistance development under different siRNA administration protocols.
- To assess the long-term efficacy and potential for resistance in siRNA cancer therapy.
Main Methods:
- Two siRNA treatment approaches were used: single high concentration (shock) and repeated increasing concentrations (gradual).
- Lipid-modified polyethylenimines were employed for siRNA delivery.
- Targets included Mcl-1, RPS6KA5, and KSP in MDA-MB-435 cancer cells, with in vivo validation.
Main Results:
- No resistance was observed in shock-treated cells.
- Gradual treatment showed initially reduced silencing efficiency, which was restored after a 7-day recovery period.
- Cellular siRNA uptake remained unaffected by pre-treatments; only JUN silencing significantly impacted cell viability.
Conclusions:
- Human cancer cells exhibited minimal resistance to repeated siRNA nanoparticle treatments.
- Temporary alterations in response were observed, but silencing efficiency was ultimately restored.
- siRNA nanoparticle therapy demonstrates potential as a robust cancer treatment with low resistance risk.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...